Taigen Biopharmaceuticals Holdings Ltd (4157) - Total Liabilities
Based on the latest financial reports, Taigen Biopharmaceuticals Holdings Ltd (4157) has total liabilities worth NT$92.38 Million TWD (≈ $2.91 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Taigen Biopharmaceuticals Holdings Ltd (4157) net asset momentum to track the company's year-over-year net asset growth rate.
Taigen Biopharmaceuticals Holdings Ltd - Total Liabilities Trend (2010–2025)
This chart illustrates how Taigen Biopharmaceuticals Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. See Taigen Biopharmaceuticals Holdings Ltd (4157) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Taigen Biopharmaceuticals Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Taigen Biopharmaceuticals Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
J.Jill Inc
NYSE:JILL
|
USA | $328.72 Million |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
India | Rs5.84 Billion |
|
Oriental Interest Bhd
KLSE:5827
|
Malaysia | RM796.13 Million |
|
Solara Active Pharma Sciences Limited
NSE:SOLARA
|
India | Rs10.36 Billion |
|
Anika Therapeutics Inc
NASDAQ:ANIK
|
USA | $45.49 Million |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
China | $32.26 Billion |
|
Alector Inc
NASDAQ:ALEC
|
USA | $262.59 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Taigen Biopharmaceuticals Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Taigen Biopharmaceuticals Holdings Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Taigen Biopharmaceuticals Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Taigen Biopharmaceuticals Holdings Ltd (2010–2025)
The table below shows the annual total liabilities of Taigen Biopharmaceuticals Holdings Ltd from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$92.38 Million ≈ $2.91 Million |
+0.46% |
| 2024-12-31 | NT$91.96 Million ≈ $2.90 Million |
-17.11% |
| 2023-12-31 | NT$110.94 Million ≈ $3.50 Million |
+44.12% |
| 2022-12-31 | NT$76.98 Million ≈ $2.43 Million |
-44.66% |
| 2021-12-31 | NT$139.11 Million ≈ $4.38 Million |
+21.75% |
| 2020-12-31 | NT$114.26 Million ≈ $3.60 Million |
-12.72% |
| 2019-12-31 | NT$130.92 Million ≈ $4.12 Million |
+38.75% |
| 2018-12-31 | NT$94.36 Million ≈ $2.97 Million |
-3.43% |
| 2017-12-31 | NT$97.71 Million ≈ $3.08 Million |
-33.90% |
| 2016-12-31 | NT$147.82 Million ≈ $4.66 Million |
-19.60% |
| 2015-12-31 | NT$183.86 Million ≈ $5.79 Million |
-25.28% |
| 2014-12-31 | NT$246.05 Million ≈ $7.75 Million |
-26.05% |
| 2013-12-31 | NT$332.71 Million ≈ $10.48 Million |
-7.87% |
| 2012-12-31 | NT$361.15 Million ≈ $11.38 Million |
+271.12% |
| 2011-12-31 | NT$97.31 Million ≈ $3.07 Million |
-98.20% |
| 2010-12-31 | NT$5.40 Billion ≈ $170.20 Million |
-- |
About Taigen Biopharmaceuticals Holdings Ltd
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic… Read more